insights_auto
Bakit tumaas ang HELP 10.07%?
Tingnan ang Higit pang Detalyechevron_right
HELP:NASDAQ
Cybin Inc
$11.80
arrow_upward
+10.07%(+1.08) 1D
$11.95
arrow_upward
+1.27% (+0.15)bedtimePagkalipas ng oras ng trabaho
Sarado: Okt 9, 4:00:01 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa HELP...
Buksan
$10.75
Mataas
$12.09
Mababa
$10.45
Avg. na dami
1.59M
Dami
1.66M
Mataas nang 52-wk
$15.15
Mababa nang 52-wk
$3.76
Beta
0.53
Mga natitirang share
73.06M
Bilang ng mga empleyado
100
Buksan
$10.75
Mataas
$12.09
Mababa
$10.45
Avg. na dami
1.59M
Dami
1.66M
Mataas nang 52-wk
$15.15
Mababa nang 52-wk
$3.76
Beta
0.53
Mga natitirang share
73.06M
Bilang ng mga empleyado
100
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Seeking Alpha
·
12 oras ang nakalipas
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout (NASDAQ:HELP)
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Tungkol sa Cybin Inc